Kyle Scarberry, MD
Urology · Winston Salem, NCNPI 1215370606
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $57,122 with a category attached, or 87.5%. Boston Scientific accounts for 92.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $51,860 and has fallen 94.5% since, to $2,872 in 2025. Among urology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $549.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$53K
- Kerecis Limited$3K
- Coloplast$405
- Johnson & Johnson$197
- Baxter Healthcare$128
- Biotissue Holdings Inc.$124
- plus $603 from 16 others
What the payments were for
- Grants$50,00088%
- Travel & lodging$3,1375%
- Food & beverage$3,9867%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 49 | $52,757 |
| Kerecis Limited | 8 | $2,908 |
| Coloplast | 10 | $405 |
| Johnson & Johnson(2 entities) | 7 | $197 |
| Baxter Healthcare | 2 | $128 |
| Biotissue Holdings Inc. | 1 | $124 |
| Urogen Pharma, Inc. | 1 | $104 |
| Sumitomo Pharma America, Inc. | 4 | $80 |
| Medical Device Business Services, Inc. | 3 | $64 |
| Olympus America Inc. | 3 | $56 |
| Aroa Biosurgery Incorporated | 2 | $41 |
| Dendreon Pharmaceuticals LLC | 1 | $36 |
| Merck | 2 | $32 |
| Endo Pharmaceuticals Inc. | 2 | $27 |
| Teleflex LLC | 1 | $26 |
| Dentsply IH Inc. | 2 | $25 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| Procept Biorobotics Corporation | 1 | $22 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $19 |
| Intuitive Surgical | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Endo USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$50,000
- Kerecis SurgiClose$9,139
- Kerecis GraftGuide$2,285
- Kerecis Omega3 SurgiClose$1,314
- AMS$1,251
- Kerecis Omega3 Marigen$842
- Kerecis Omega3 GraftGuide$401
- TITAN$176
- GENERAL - THERAPIES$138
- NEOX$124
- CLARIX$124
- AMS 700$115
- GENESIS$110
- RYBREVANT$107
- CARVYKTI$107
- JELMYTO$104
- TISSEEL$104
How this compares
$57,122 in reported general payments places this provider in the 90th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 128 | $71,098 |
| GemtesaVibegron | 61 | $42,973 |
| Mirabegron ErMirabegron | 12 | $7,769 |
| Trospium Chloride ErTrospium Chloride | 15 | $4,799 |
| Tamsulosin Hcl | 351 | $4,567 |
| Oxybutynin Chloride ErOxybutynin Chloride | 34 | $1,613 |
| Gentamicin Sulfate | 106 | $1,517 |
| Trospium Chloride | 22 | $1,263 |
| Trimethoprim | 26 | $1,168 |
| Testosterone | 16 | $1,131 |
| Finasteride | 84 | $979 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 33 | $682 |
| Potassium Citrate ErPotassium Citrate | 18 | $648 |
| Cephalexin | 61 | $619 |
| NitrofurantoinNitrofurantoin Macrocrystal | 33 | $600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $17 | $71,098128 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $80 | $42,97361 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 434 urology providers in North Carolina.
Other urology in Winston Salem
- Ryan TerleckiWinston Salem$219K
- Soroush Rais-BahramiWinston Salem$66K
- Ethan MatzWinston Salem$62K
- Connor PolicastroWinston Salem$53K
- Colin KleinguetlWinston Salem$52K
- Anthony AtalaWinston Salem$26K
- Gopal BadlaniWinston Salem$25K
- Alejandro RodriguezWinston Salem$17K
- John SmithWinston Salem$17K
- Robert LippittSmithfield$11.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.